This trial is evaluating whether Apalutamide will improve 2 primary outcomes and 12 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 12 months.
This trial requires 504 total participants across 3 different treatment groups
This trial involves 3 different treatments. Apalutamide is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"The data show that despite widespread belief, it is not possible to cure prostate cancer. However, it is also evident that the disease can be made to go into remission. To do this, patients need to be well informed and they need to be convinced that their life is not at risk, that the disease does not need to be repeated examination or to be treated with aggressive chemotherapy, and that the disease has a cure within their grasp if they choose to take its cure." - Anonymous Online Contributor
"In the past 5 years, the number of men diagnosed with prostatic cancer has risen to nearly 700,000 per year. Over 20,000 of these men have cancer that is localized, meaning that it has been halted by surgery, radiation therapy, or hormonal therapy. If cancers are found to have spread to lymph nodes or other areas of the body, and if they are found at the surface of the organ, the disease is considered "organ-confined". As prostate cancer has become more common, it is important for health-care providers to understand these factors that affect the course and outcome of disease." - Anonymous Online Contributor
"The symptom pattern of advanced prostate cancer is similar to that of low-risk patients with localized disease. The PSA is a good parameter to detect the disease." - Anonymous Online Contributor
"We determined the role of environmental factors in the etiology of prostate cancer. Because of the limited sample size of this study and the limited study time window, this conclusion should be confirmed with the aid of larger studies and longer follow-up periods." - Anonymous Online Contributor
"Within the United States there is significant variation in rates of diagnosis of prostate cancer by race and by age. However, age remains the strongest predictor of prostate cancer-specific survival." - Anonymous Online Contributor
"The American Academy of Family Physicians (AAFP) consensus guidelines recommend treating men with prostate cancer surgically after they have Gleason grade 3 or 4 disease, low urinary flow, high-grade Gleason tumors, and large tumor volumes, and in whom a curative therapy is appropriate. Appropriate therapy is indicated in all men with low, intermediate, and high Gleason grade stages, high tumor volumes, and low-flow obstruction." - Anonymous Online Contributor
"Apalutrac therapy for prostate cancer is effective, especially in terms of PSA decline. In this retrospective study, patients receiving the drug in the first 3 months of treatment had a lower TTP compared to those treated afterwards." - Anonymous Online Contributor
"APA is being investigated in the clinic for a variety of uses and at different dosages. We are aware of 4 trials. These trials have been designed, and at the present time a number of subjects are available in each, with completion and/or reporting in progress." - Anonymous Online Contributor
"In the UK, in contrast to other continents, where [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) has become more common, overall and cancer-specific survival rates show no significant improvement. The survival advantage in North America, particularly in African Americans, may be explained by survival differences by stage, and it is more likely that this survival advantage is due to earlier detection and, therefore, more effective referral to treatment as compared to other continents, where only a minority of patients are diagnosed with prostate cancer at an early stage." - Anonymous Online Contributor
"In Japanese patients with [metastatic prostate cancer](https://www.withpower.com/clinical-trials/metastatic-prostate-cancer) or castration-resistant prostate cancer, apalutamide reduced the PSA level and significantly improved the time to progression following 12 weeks of treatment. Apalutamide has shown to be effective and well tolerated in Japanese patients with prostate cancer." - Anonymous Online Contributor
"It should be emphasized that more research is required to clarify if the risk of prostate cancer can be partially or completely prevented by reducing the exposure to some risk factors that cause chronic inflammation and/or oxidative stress." - Anonymous Online Contributor
"Compared with placebo, long-term apalutamide treatment is associated with similar rates of adverse events. There were no new or serious adverse effects reported in people taking apalutamide. This confirms that there are no risks that warrant the suspension of prescribing adjuvant apalutamide for patients diagnosed with localized prostate cancer." - Anonymous Online Contributor